Sol-Gel Technologies Ltd. SLGL
Sol-Gel Technologies Ltd. (Nasdaq: SLGL) is a dermatology drug developer. Its lead program, SGT-610 (patidegib gel 2%), is in Phase 3 for chronic use and prevention of new basal cell carcinomas in Gorlin syndrome.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SGT-610 (patidegib gel 2%) | Gorlin syndrome (BCC prevention) | small molecule | Phase 3 |
| SGT-610 (high-frequency BCC) | high-frequency basal cell carcinoma | small molecule | Pre-clinical |
| SGT-210 platform | indications with significant unmet need | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.